# Advanced Development of Antibacterial Countermeasures

> **NIH NIH N01** · SPERO THERAPEUTICS, INC. · 2021 · $2,089,779

## Abstract

To support the advanced development of a promising candidate therapeutic for resistant bacteria. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

## Key facts

- **NIH application ID:** 10410065
- **Project number:** 75N93021C00022-0-9999-1
- **Recipient organization:** SPERO THERAPEUTICS, INC.
- **Principal Investigator:** TROY LISTER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,089,779
- **Award type:** —
- **Project period:** 2021-05-17 → 2023-01-16

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10410065

## Citation

> US National Institutes of Health, RePORTER application 10410065, Advanced Development of Antibacterial Countermeasures (75N93021C00022-0-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10410065. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*